It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on ...

A study of older adults showed that 6% had depression, with higher prevalences in certain groups, including women, those who ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...

Health-care companies were flat as deal activity was offset by fears of more regulation in the sector. Orthopedic surgery device maker Stryker agreed to buy medical technology maker Inari Medical for ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

Neumora Therapeutics Inc (NMRA) stock saw a modest uptick, ending the day at $2.17 which represents a slight increase of $0.20 or 10.15% from the prior close of $1.97. The stock opened at $2.23 and ...

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing ...

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

Investors appeared to have entered the new year with cautious footing, with uncertainties around future Fed rate cuts and ...

Neumora Therapeutics announced that its antidepressant candidate, navacaprant, did not meet the primary endpoint in a Phase 3 study for major depressive disorder.

Meanwhile, increased rates of cancer in the under 50 crowd may be caused by gut issues; certain foods, including licorice, may help covid patients; Neumora Therapeutics depression treatment fails ...